5-Norbornene-endo-2,3-dicarboximide
- Catalog NO.:A928515
- CAS No. : 6265-30-1
- Molecular Formula:C9H9NO2
- Molecular Weight: 163.17
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
COA
Product Details
CAS Number | 6265-30-1 | Appearance | |
Catalog Number | A928515 | MDL Number | MFCD13183883 |
Molecular Formula | C9H9NO2 | Molecular Weight | 163.17 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | rel-(3aR,4S,7R,7aS)-3a,4,7,7a-Tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 | Packing Group |
Description
Rilpivirine is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011. A fixed-dose drug combining rilpivirine with emtricitabine and tenofovir, was approved by the U.S. Food and Drug Administration in August 2011 under the brand name Complera. |